Loading...
XNAS
ILMN
Market cap12bUSD
Apr 03, Last price  
76.42USD
1D
-6.67%
1Q
-43.81%
Jan 2017
-40.32%
Name

Illumina Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.77
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.31%
Rev. gr., 5y
4.29%
Revenues
4.37b
-2.93%
73,501,000184,586,000366,799,000573,225,000666,324,000902,741,0001,055,535,0001,148,516,0001,421,178,0001,861,358,0002,219,762,0002,398,373,0002,752,000,0003,333,000,0003,543,000,0003,239,000,0004,526,000,0004,584,000,0004,504,000,0004,372,000,000
Net income
-1.22b
L+5.34%
-20,874,00039,968,000-278,359,00050,477,00072,281,000124,891,00086,628,000151,254,000125,308,000353,351,000461,559,000462,649,000726,000,000826,000,0001,002,000,000656,000,000762,000,000-4,404,000,000-1,161,000,000-1,223,000,000
CFO
837m
+75.10%
-9,008,00039,000,00056,294,00087,882,000174,496,000272,573,000358,140,000291,873,000386,421,000501,271,000659,596,000687,238,000875,000,0001,142,000,0001,051,000,0001,080,000,000545,000,000392,000,000478,000,000837,000,000
Earnings
Apr 30, 2025

Profile

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
URL
https://www.illumina.com/
IPO date
Jun 28, 2000
Employees
11,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122023‑002022‑002021‑002019‑122018‑122017‑122017‑002016‑00
Income
Revenues
4,372,000
-4.62%
4,504,000
-0.49%
4,584,000
1.28%
Cost of revenue
2,680,000
3,114,000
2,933,000
Unusual Expense (Income)
NOPBT
1,692,000
1,390,000
1,651,000
NOPBT Margin
38.70%
30.86%
36.02%
Operating Taxes
44,000
44,000
68,000
Tax Rate
2.60%
3.17%
4.12%
NOPAT
1,648,000
1,346,000
1,583,000
Net income
(1,223,000)
-72.23%
(1,161,000)
-252.36%
(4,404,000)
-677.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
(60,000)
67,000
9,000
BB yield
0.28%
-0.30%
-0.03%
Debt
Debt current
499,000
86,000
1,248,000
Long-term debt
2,598,000
2,863,000
2,975,000
Deferred revenue
63,000
Other long-term liabilities
339,000
620,000
649,000
Net debt
1,877,000
1,699,000
1,975,000
Cash flow
Cash from operating activities
837,000
478,000
392,000
CAPEX
(128,000)
(195,000)
(466,000)
Cash from investing activities
(178,000)
(231,000)
(591,000)
Cash from financing activities
(570,000)
(1,210,000)
1,000,000
FCF
1,579,000
1,693,000
1,887,000
Balance
Cash
1,220,000
1,054,000
2,037,000
Long term investments
196,000
211,000
Excess cash
1,001,400
1,024,800
2,018,800
Stockholders' equity
(1,218,000)
(18,000)
1,147,000
Invested Capital
6,473,000
8,645,000
9,546,000
ROIC
20.58%
12.53%
14.15%
ROCE
32.20%
16.11%
15.53%
EV
Common stock shares outstanding
159,000
158,000
157,000
Price
135.27
-33.10%
139.24
-63.40%
202.20
-46.85%
Market cap
21,507,930
-32.25%
21,999,920
-61.70%
31,745,400
-44.74%
EV
23,384,930
23,698,920
33,720,400
EBITDA
2,046,000
1,822,000
2,045,000
EV/EBITDA
11.43
13.01
16.49
Interest
100,000
77,000
26,000
Interest/NOPBT
5.91%
5.54%
1.57%